Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02932098 · ClinicalTrials.gov registry record · NA
Post-Operative Gynecological Oncology App Study
A NA study of Genital Neoplasm, Female, sponsored by University of Tennessee.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 3
- Study locations
NCT02932098: Completed NA study of Genital Neoplasm, Female, sponsored by University of Tennessee.
NCT02932098 is a NA study of Genital Neoplasm, Female that has completed, run by University of Tennessee. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02932098, a NA study of Genital Neoplasm, Female, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 3
- Study locations
Study Summary
Purpose: The purpose of this study will be to test the use of a web-based mobile application (app) initiated at the time of hospital discharge to engage and monitor patients in order to efficiently deliver better outcomes. The mobile app will be used to remind patients of discharge instructions, assess adherence treatment regimens, and evaluate symptoms. Rationale: Approximately 60% of patients with ovarian cancer have advanced stage disease at diagnosis, and thus aggressive surgical procedures are often medically necessary. Recent evidence suggests that nearly one in five patients hospitalized for ovarian cancer surgery will be readmitted within 30 days of discharge. Patients readmitted within 30 days have a 50% increase in one-year mortality rates and significantly increased costs of care. In addition, many of the conditions and complications that led to readmission could potentially have been avoided with more intensive post-surgical follow-up care. Mobile health technologies can effectively and efficiently connect patients with their healthcare team and have been shown to improve treatment adherence and reduce avoidable ER visits and hospitalizations.
Primary Outcome
The primary data analysis will adhere to the intention-to-treat principle and in the final analysis, the participants will be categorized according to their initial randomization. Investigators will measure changes in quality of life from baseline and at 30-days, and compare changes between the two study arms.
Conditions Studied
Interventions
- BEHAVIORAL Clinical Alerts
- BEHAVIORAL Discharge instructions reminders
- BEHAVIORAL Prompts to report symptoms via the web-enabled app
Study Locations (3)
Tennessee
- West Cancer Center, MIDTOWN, 1588 Union Ave. - Memphis
- West Cancer Center, EAST MEMPHIS, 7945 Wolf River Blvd - Memphis
Mississippi
- West Cancer Center, DESOTO, 7668 Airways Blvd. - Southaven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-08 |
| Est. Completion | 2018-03 |
| Phase | NA |
What the finished NCT02932098 record still lists
NCT02932098 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Genital Neoplasm, Female appearing as the primary indexed condition, and to 3 interventions - of which Clinical Alerts is the first listed.
NCT02932098 reports a single indexed study location in Tennessee, Mississippi.
Frequently Asked Questions
What is clinical trial NCT02932098 about?
NCT02932098 is a clinical study titled "Post-Operative Gynecological Oncology App Study". Purpose: The purpose of this study will be to test the use of a web-based mobile application (app) initiated at the time of hospital discharge to engage and monitor patients in order to efficiently deliver better outcomes. The mobile app will be used to remind patients of discharge instructions, ass...
What is the current status of trial NCT02932098?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2016-08. Estimated completion is 2018-03.
What conditions does trial NCT02932098 study?
This clinical trial studies the following conditions: Genital Neoplasm, Female.
What interventions are being tested in trial NCT02932098?
The interventions under investigation include: Clinical Alerts (BEHAVIORAL), Discharge instructions reminders (BEHAVIORAL), Prompts to report symptoms via the web-enabled app (BEHAVIORAL).
Who is sponsoring clinical trial NCT02932098?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02932098 being conducted?
This trial has 3 study locations across Mississippi, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genital Neoplasm, Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02932098's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia